Furthermore, increased stromal B cell density in pre-treatment biopsy samples of recurrent/metastatic HNSCC identifies a subgroup of PD-L1 expressors with better survival outcomes after anti-PD-1 treatment [49]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.